High-Risk Non-Muscle-Invasive Bladder Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CG Oncology
CG OncologyIRVINE, CA
1 program
1
Cretostimogene GrenadenorepvecPhase 21 trial
Active Trials
NCT06567743RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
CG OncologyCretostimogene Grenadenorepvec

Clinical Trials (1)

NCT06567743CG OncologyCretostimogene Grenadenorepvec

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Start: Sep 2024Est. completion: Dec 2027
Phase 2Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)